Register for email alerts and news feeds:
This journal | BMJ Group
rss
Heart 1998;79:56-58; doi:10.1136/hrt.79.1.56
Copyright © 1998 BMJ Publishing Group Ltd & British Cardiovascular Society

Heart 1998;79:56-58 ( January )

Relation between bradycardia dependent long QT syndrome and QT prolongation by disopyramide in humans

Hiroshi Furushima, Shinichi Niwano, Masaomi Chinushi, Kouji Ohhira, Akira Abe, Yoshifusa Aizawa

The First Department of Internal Medicine, Niigata University School of Medicine, Niigata, 1-754 Asahi-machi, Niigata, 951 Japan

Correspondence to: Dr Furushima.

Accepted for publication 31 July 1997

Background---Recent molecular biological investigations have identified abnormal genes in familial forms of long QT syndrome, but in bradycardia dependent acquired long QT syndrome, no such genetic abnormality has yet been identified.
Objective---To investigate the relation between the responses of QT interval to pacing change and to disopyramide.
Methods---This study included 13 patients with bradyarrhythmia who had undergone pacemaker implantation. The patients were divided into two groups: group I (n = 8), patients with QT prolongation (QT interval >=  500 ms) during bradycardia; group II (n = 5), patients without QT prolongation (QT interval < 500 ms) during bradycardia. The responses of QT interval caused by the change of pacing rate were determined and compared with the changes of the QT interval after disopyramide administration.
Results---The QT interval in group I was significantly longer than that in group II when the pacing rate was decreased from 110 to 50 beats/min: mean (SD) 451 (16) v 416 (17) ms at 90 beats/min (p = 0.0033), and 490 (19) v 432 (18) ms at 70 beats/min (p = 0.0002), respectively. The QT interval was prolonged significantly by disopyramide in both groups, but the change was more pronounced in group I than in group II: 78 (33) v 35 (10) ms (p < 0.05).
Conclusions---This study suggests that the patients showing bradycardia dependent QT prolongation are also more markedly affected by disopyramide and that abnormal potassium channel may be the underlying mechanism.

Keywords: bradycardia;  long QT syndrome;  disopyramide

© 1998 by Heart
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Leotta, E., Patejunas, G., Murphy, G., Szokol, J., McGregor, L., Carbray, J., Hamawy, A., Winchester, D., Hackett, N., Crystal, R., Rosengart, T. (2002). Gene therapy with adenovirus-mediated myocardial transfer of vascular endothelial growth factor 121 improves cardiac performance in a pacing model of congestive heart failure. J. Thorac. Cardiovasc. Surg. 123: 1101-1113 [Abstract] [Full Text]  
  • Korewicki, J., Rywik, S., Rywik, T. (2002). Management of heart failure patients in Poland. Eur J Heart Fail 4: 215-219 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Show me all >>